Actively Recruiting
COMPERA / COMPERA-KIDS
Led by Technische Universität Dresden · Updated on 2025-08-24
14000
Participants Needed
7
Research Sites
1017 weeks
Total Duration
On this page
Sponsors
T
Technische Universität Dresden
Lead Sponsor
G
GWT-TUD GmbH
Collaborating Sponsor
AI-Summary
What this Trial Is About
In view of the manifold options for mono- and combination therapy that have now emerged for patients with pulmonary (arterial) hypertension (PH/PAH), controlled clinical trials can only provide part of the information needed for optimal management. In order to gather adequate data on PAH/PH treatment in routine clinical care, the ongoing COMPERA registry prospectively documents consecutive patients with newly initiated treatment of PAH/PAH since May 2007. The internet-based registry fulfills high quality standards through several measures (planned minimum centre contribution of at least 10 patients per year, automated plausibility checks of data at entry, queries, monitoring with source data verification in \>50% of participating centers). It can be applied, among further purposes, for quality assurance: individual centers can confidentially compare their results with the combined outcome of other centers and the recommendations from guidelines. It is expected that the register contributes to optimization of specific drug therapy for PAH and PH. Since July 2013, also children of any age can be documented (COMPERA-KIDS).
CONDITIONS
Official Title
COMPERA / COMPERA-KIDS
Who Can Participate
Eligibility Criteria
You may qualify if you...
- All age groups are eligible
- Written informed consent is required
- Diagnosis of pulmonary hypertension (PH) including idiopathic PAH, PAH associated with connective tissue diseases, congenital heart defects, HIV infection, or portopulmonary form
- Chronic thromboembolic PH (CTEPH) patients
- PH related to left heart diseases or pulmonary diseases
- "Relative PH" after specific heart surgeries such as cavopulmonary anastomosis or Fontan-type surgery
- Newly initiated therapy with ERA, PDE-5 inhibitors, sGC stimulators, or prostacyclins within 3 months before first documentation
- PAH-CHD patients on maintenance therapy or with severe pulmonary vascular disease such as Eisenmenger physiology are also eligible
You will not qualify if you...
- Patients on maintenance therapy with any ERA, PDE-5 inhibitor, prostacyclin, or sGC stimulator longer than 3 months before first documentation (except PAH-CHD patients)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Dept. of Pneumology, University
Leuven, Belgium
Actively Recruiting
2
DRK-Klinikum Köpenick
Berlin, Germany
Actively Recruiting
3
Lung Centre, University of Giessen
Giessen, Germany
Actively Recruiting
4
Department of Pulmology; Hannover Medical School
Hanover, Germany
Actively Recruiting
5
German Heart Centre
Munich, Germany
Actively Recruiting
6
Department of Cardiovascular and Respiratory Sciences, University La Sapienza
Rome, Italy
Actively Recruiting
7
Dept. for Rheumatology, University Hospital
Zurich, Switzerland
Actively Recruiting
Research Team
D
David Pittrow, MD, PhD
CONTACT
M
Marius M. Hoeper, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here